Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
β Scribed by Gianmauro Numico; Ornella Garrone; Vincenzo Dongiovanni; Nicola Silvestris; Ida Colantonio; Gianna Di Costanzo; Cristina Granetto; Marcella Occelli; Elena Fea; Abdelamid Heouaine; Milena Gasco; Marco Merlano
- Book ID
- 102106377
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 79 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Multiple trials have been performed to evaluate secondβline clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. ## METHODS Patients with advanced NSCLC who had
## Abstract ## BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in patients with advanced nonsmall cell lung carcinoma (NSCLC). The primary objective was survival. Secondary objectives we
## Background: The objective of this phase ii study was to evaluate the concept of sequential chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma (nsclc) by the administration of carboplatin plus gemcitabine followed by of paclitaxel. ## Methods: Patients with sta